Alumis Reports Strong Week 48 Psoriasis Data, But Core Risks Remain

What happened

Alumis announced Q3 2026 financial results and highlighted new Phase 3 data showing envudeucitinib achieved the highest publicly reported Week 48 PASI 100 response rate among oral psoriasis therapies, reinforcing its efficacy leadership. The update, however, does not address the drug's twice-daily dosing, which remains a competitive disadvantage against once-daily rivals Takeda's zasocitinib and J&J's icotrokinra. Financial details were not provided in the headline, but the company is expected to report continued significant cash burn with no product revenue. The stock may react positively to the efficacy data, but the fundamental investment case remains challenged by competition and capital intensity. Overall, the news is incremental and consistent with prior positive efficacy data, but does not resolve the core risks.

Implication

The new data supports envudeucitinib's potential to be a best-in-class oral, but twice-daily dosing still handicaps it versus once-daily competitors, and payer pressure may limit market share. The company's cash burn likely remains elevated, and lupus Phase 2b data in Q3 2026 is still a binary event. At current prices, the market already discounts much of the positive psoriasis data, leaving limited upside. Any rally on this news could be used to trim positions, while a pullback toward $17 would offer a more favorable risk-reward. Overall, the investment thesis remains unchanged: potential sell above $28, attractive entry below $17.

Thesis delta

The long-term efficacy data marginally strengthens envudeucitinib's clinical profile but does not change the valuation or risk assessment. The thesis remains a potential sell/trim at current levels, with a more attractive entry near $17. No shift in conviction.